Generic Biotech Drugs Stymied By Slow, Costly Process

Interesting – the generics are coming to biotech, but it is and will take some time. Part of the ongoing debate in pharmaceuticals on the appropriate balance between encouraging innovation through strong intellectual property protection (essentially guaranteeing monopoly-type profits for a number of years) and cost-effectiveness for healthcare systems.

Generic Biotech Drugs Stymied By Slow, Costly Process.

About these ads

What do you think?

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s